Completion of sale of VelosBio

Arix Bioscience PLC (ARIX)
Completion of sale of VelosBio

18-Dec-2020 / 08:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

 

Completion of sale of VelosBio

 

LONDON, 18 December 2020: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the completion of the previously announced sale of its portfolio company VelosBio Inc. ("VelosBio"), to Merck & Co., Inc., Kenilworth NJ., USA, for final all cash consideration of $2.75 billion.

 

The trade sale of VelosBio generates gross proceeds of $187.0 million (£138.5 million)[1] to Arix, representing a 12.5x return on its original investment of $15.0 million (£11.8 million) and an internal rate of return (IRR) of 328%.

 

The tax treatment of this transaction will be detailed within Arix's 2020 Annual Report and Accounts, to be published in March 2021.

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

Optimum Strategic Communications

Supriya Mathur, Shabnam Bashir, Manel Mateus

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

For more information please visit: www.arixbioscience.com


[1] At GBP/USD FX rate of 1.3500

 



ISIN: GB00BD045071
Category Code: MSCU
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 89913
EQS News ID: 1155675

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1155675&application_name=news&site_id=financialexpress
UK 100

Latest directors dealings